Loading
ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade.
A cyclic dinucleotide STING agonist from Aduro (partnered with Novartis). Phase 1 monotherapy and combinations with spartalizumab or ipilimumab produced single-digit response rates; Novartis returned rights in 2019 and Aduro discontinued the programme in 2020. Merck's MK-1454 followed the same path. The pathway remains important (it mediates immune effects of radiation and ADCs), and systemic and antibody-conjugated STING agonists continue.
Lesson: intratumoural delivery to one lesion rarely produces systemic immunity in humans as it does in mice; pharmacology (rapid clearance, dosing) matters as much as the target.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Synthetic cyclic dinucleotide activating STING → TBK1 → IRF3 → type I interferon.
1.ADU-S100 (MIW815) slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ADU-S100" OR ABSTRACT:"ADU-S100" OR TITLE:"MIW815" OR ABSTRACT:"MIW815") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADU-S100 (MIW815), not a curated reading list.
Shares Cold tumours and the immunosuppressive microenvironment, Melanoma and the tag failure.
Shares Head and neck squamous cell carcinoma and the tag failure.
Shares Head and neck squamous cell carcinoma and the tag failure.
Shares Melanoma and the tag failure.
Shares Cold tumours and the immunosuppressive microenvironment and the tag failure.
Shares Melanoma and the tag failure.
Shares Melanoma and the tag failure.
Shares Cold tumours and the immunosuppressive microenvironment and the tag failure.